Comparing different transcatheter heart valves (THVs) is necessary to obtain relevant information that facilitates the selection of the appropriate valve for each patient. A previous study compared early outcomes between the self-expanding ACURATE Neo2 valve and the balloon-expandable Sapien 3 Ultra valve. However, there are no comparative data on these two valves in the medium term. This is a retrospective, multicenter study.
The primary endpoint (PEP) was a composite of all-cause mortality, stroke, and rehospitalization after one year.
A total of 1166 patients were included in the ACURATE Neo2 group and 940 patients in the Sapien 3 Ultra group. The mean age was 82 years, and the mean EuroSCORE was 3.2. After propensity score matching to homogenize the samples, 743 patients from both groups were analyzed. Regarding the results, there were no statistically significant differences between the two groups (p=0.714).
Conclusion
The use of the ACURATE Neo2 and Sapien 3 Ultra valves showed similar results at one year of follow-up in terms of a composite of all-cause mortality, stroke, and rehospitalization. These medium-term results suggest that both scaffolds may be equivalent alternatives. However, randomized and long-term studies are required to confirm these findings.
Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.
Original Title: One- year outcomes of transcatheter aortic valve replacement using a self expanding versus balloon expandable transcatheter aortic valve.
Reference: Won-Keun Kim et al.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology